Edition:
United Kingdom

Sinovac Biotech Ltd (SVA.OQ)

SVA.OQ on NASDAQ Stock Exchange Global Select Market

7.88USD
11 Dec 2017
Change (% chg)

$0.13 (+1.68%)
Prev Close
$7.75
Open
$7.78
Day's High
$7.89
Day's Low
$7.78
Volume
55,097
Avg. Vol
52,552
52-wk High
$7.98
52-wk Low
$4.60

Latest Key Developments (Source: Significant Developments)

Sinovac Biotech Announces Update On Nasdaq Matters
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Sinovac Biotech Ltd ::SINOVAC BIOTECH ANNOUNCES UPDATE ON NASDAQ MATTERS.SINOVAC BIOTECH- ‍NASDAQ HEARINGS PANEL GRANTED REQUEST TO EXTEND STAY OF SUSPENSION IN TRADING OF CO'S COMMON SHARES PENDING HEARING ON JAN 11, 2018​.  Full Article

Sinovac reports Q4 earnings per share $0.08
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Sinovac Biotech Ltd :Sinovac files 2016 annual report on form 20-F and reports unaudited fourth quarter 2016 financial results.Q4 earnings per share $0.08.Q4 sales rose 36.7 percent to $31.4 million.  Full Article

Sinovac posts Q2 loss of $0.17/share
Tuesday, 23 Aug 2016 

Sinovac Biotech Ltd: Sinovac reports unaudited second quarter 2016 financial results . Q2 loss per share $0.17 . Q2 non-GAAP loss per share $0.15 from continuing operations . Q2 sales $1.4 million versus $18.5 million . Will seek new commercial bank loans to finance commercialization of pipeline products . "Expect that sales in our fiscal second half of year will be much stronger than first half" .Expects that its current cash position will be able to support its operations for next 12 months.  Full Article

Sinovac says Shandong incident had material effect on revenues in Q1
Thursday, 26 May 2016 

Sinovac Biotech Ltd : Shandong incident had a material effect on our revenues in Q1 and we expect that trend will continue into Q2 . Company expects that its current cash position will be able to support its operations for next 12 months . Sinovac reports unaudited first quarter 2016 financial results . Q1 non-gaap loss per share $0.01 from continuing operations . Q1 earnings per share $0.02 .Q1 sales rose 19 percent to $11 million.  Full Article

Sinovac Biotech Ltd announces receipt of preliminary non-binding proposal to acquire the Company
Monday, 1 Feb 2016 

Sinovac Biotech Ltd:Received a preliminary non-binding proposal letter from Weidong Yin, chairman, president and chief executive officer of the Company, SAIF Partners IV L.P. and/or its affiliates, to acquire all of the outstanding common shares of the Company.  Full Article

BRIEF-Sinovac Biotech Announces Update On Nasdaq Matters

* SINOVAC BIOTECH- ‍NASDAQ HEARINGS PANEL GRANTED REQUEST TO EXTEND STAY OF SUSPENSION IN TRADING OF CO'S COMMON SHARES PENDING HEARING ON JAN 11, 2018​ Source text for Eikon: Further company coverage: